Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: majaman1978 who wrote (114)	1/5/1998 3:38:00 PM
From: makin_dough99	Respond to of 4028

Mike Skillern Appointed President of Cryogenic Solutions, Inc HOUSTON (Jan. 5) BUSINESS WIRE -Jan. 5, 1998--CRYOGENIC SOLUTIONS, INC (OTC BB:CYGS) named founder, vice president, and director, Mike Skillern as president, after deciding in a December 11th meeting, not enter into a three year employment agreement with Steve Sloat. Skillern assumed office on December 16th following Sloat's 90-day review period agreed to by the parties in September of 1997. In January, CSI plans to ask shareholders to ratify a corporate name change to US Biogenix, a name that better describes the scope and focus of the company's primary research and development activities. "The original name reflected the use of cryopreservation in our proposed pregnancy suspension technology," explained Skillern, "but unfortunately the social, ideological, and political opponents made it impossible to deliver that service so we redirected our efforts toward telomere biology and its applications to aging, cancer and other therapies." In April, 1997, The company licensed technology and began perfecting the patent for their TeloVector(TM) which can synthesize sequence specific single strands of DNA (ssDNA) in cells in the body (in vivo) to repair telomere ends shortened during cell division (mitosis). The processive elongation of telomeric repeats has been demonstrated to reverse aging in cells in various laboratory studies. In other studies the same technology has also killed cancer cells. "The company is focusing its full resources to optimizing the value of the TeloVector(TM) in all its manifestations," said Executive Vice President, Dell Gibson. "We have full confidence in the gerontology (aging) and oncology (cancer) applications. Cell Studies are beginning and we hope to move on to animal studies in the second quarter." CSI will spin off the aquaculture division into a separate corporation which is considered to have adequate potential to deserve a independent dedicated staff. The research continues to be directed by Craig Tomlinson, PhD. Currently, there is no existing commercial aquaculture operation the matches the combination of advanced technologies envisioned by the company. "We believe we can grow more shrimp, faster and larger," said Tomlinson, "and produce a 'clean' shrimp, free of environmental or viral contaminants." CSI will concentrate on perfecting and expanding the scope of its Telovector(TM) technologies, including viral research which is expected to have application to the shrimp farming enterprise. CONTACT: Cryogenic Solutions Inc., Houston Dell Gibson, 713/780-1399 cygs@wt.net. URL: biogenix.com